Stockwatch: biotech stocks propped by dubious market research
This article was originally published in Scrip
Executive Summary
This is the time of year when I supervise MPhil students from the University of Cambridge who are researching and writing their dissertations. At this level, students should be able to demonstrate some quantitative analysis. In an assignment that only lasts a few months, that usually means that they conduct some primary market research. Thankfully, students can learn from my mistakes: I never want them to have that nauseous feeling you get when you read the results of a $30,000 market research study and realize that you did not have the most commercially important question in the questionnaire.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.